[go: up one dir, main page]

MX2016004551A - Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis. - Google Patents

Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.

Info

Publication number
MX2016004551A
MX2016004551A MX2016004551A MX2016004551A MX2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A
Authority
MX
Mexico
Prior art keywords
semaphorine
aterosclerosis
treatment
binding molecules
subject
Prior art date
Application number
MX2016004551A
Other languages
English (en)
Other versions
MX385575B (es
Inventor
Maurice Zauderer
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX2016004551A publication Critical patent/MX2016004551A/es
Publication of MX385575B publication Critical patent/MX385575B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos para reducir, inhibir, suprimir y/o retrasar el crecimiento de placa aterosclerótica o neovascularización en un sujeto que tiene aterosclerosis, que comprende administrar al sujeto una cantidad efectiva de una molécula de ligación aislada que se liga específicamente a Semaforina-4D (SEMA4D) o a su receptor Plexina-B1 de alta afinidad.
MX2016004551A 2013-10-10 2014-10-10 Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis. MX385575B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889421P 2013-10-10 2013-10-10
PCT/US2014/060129 WO2015054628A1 (en) 2013-10-10 2014-10-10 Use of semaphorin-4d binding molecules for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
MX2016004551A true MX2016004551A (es) 2016-07-22
MX385575B MX385575B (es) 2025-03-18

Family

ID=52809873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004551A MX385575B (es) 2013-10-10 2014-10-10 Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis.

Country Status (18)

Country Link
US (1) US9512224B2 (es)
EP (1) EP3054976B1 (es)
JP (2) JP6760840B2 (es)
KR (1) KR102366682B1 (es)
CN (1) CN105848679A (es)
AU (1) AU2014331683B2 (es)
BR (1) BR112016008010A2 (es)
CA (1) CA2926944C (es)
DK (1) DK3054976T3 (es)
EA (1) EA037551B1 (es)
ES (1) ES2821814T3 (es)
IL (1) IL244976B (es)
MX (1) MX385575B (es)
NZ (1) NZ630881A (es)
PT (1) PT3054976T (es)
SG (1) SG11201602807PA (es)
WO (1) WO2015054628A1 (es)
ZA (1) ZA201602577B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011718A (es) 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
US20130095118A1 (en) 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP3013350B1 (en) 2013-06-25 2020-01-08 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
CN109563143A (zh) 2016-08-02 2019-04-02 瓦西尼斯公司 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法
CN106474559B (zh) * 2016-11-30 2019-07-12 西南交通大学 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法
SG11201906670PA (en) * 2017-02-22 2019-08-27 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
CN106983919B (zh) * 2017-03-06 2019-07-12 西南交通大学 一种Sema 4D-VEGF涂层的构建方法及应用
NZ758300A (en) 2017-05-05 2025-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
CN108499220B (zh) * 2018-04-25 2020-07-31 山东纯江环境科技有限公司 石墨烯/聚丙烯非织造布过滤网制备方法及其应用
CN109125731B (zh) * 2018-10-22 2019-10-25 华中科技大学同济医学院附属协和医院 Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用
JP7743447B2 (ja) * 2020-06-19 2025-09-24 ザ ジェネラル ホスピタル コーポレイション 近赤外自己蛍光イメージングシステム及び方法
AU2021297152A1 (en) * 2020-06-25 2023-02-02 The Sydney Children's Hospitals Network Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
KR102847091B1 (ko) * 2022-08-25 2025-08-21 부산대학교 산학협력단 혈관석회화 동반 만성신부전에서 세마포린 4d의 용도
CN116949097B (zh) * 2023-09-20 2023-12-12 江苏集萃药康生物科技股份有限公司 一种sema4d人源化小鼠模型的构建方法及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
CA2286477A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005000900A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
RU2398777C2 (ru) 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
US20060147449A1 (en) * 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
EP1871484A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Sema4d in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
ATE494306T1 (de) 2007-02-14 2011-01-15 Vaccinex Inc Humanisierte anti-cd100-antikörper
PE20091378A1 (es) 2008-01-10 2009-10-14 Genentech Inc Polipeptidos agonistas plexind1
MX2011011718A (es) * 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
EP2579895A4 (en) 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
US9447191B2 (en) 2011-05-13 2016-09-20 National University Corporation Tokyo Medical And Dental University Osteogenesis promoter
US20130095118A1 (en) 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP3013350B1 (en) 2013-06-25 2020-01-08 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Also Published As

Publication number Publication date
EP3054976A1 (en) 2016-08-17
WO2015054628A1 (en) 2015-04-16
US20150104462A1 (en) 2015-04-16
CN105848679A (zh) 2016-08-10
JP6760840B2 (ja) 2020-09-23
EP3054976A4 (en) 2017-05-17
ES2821814T3 (es) 2021-04-27
EA037551B1 (ru) 2021-04-13
AU2014331683B2 (en) 2019-07-11
NZ630881A (en) 2016-03-31
DK3054976T3 (da) 2020-09-28
CA2926944C (en) 2023-08-08
KR20160062167A (ko) 2016-06-01
CA2926944A1 (en) 2015-04-16
KR102366682B1 (ko) 2022-02-22
JP2019108359A (ja) 2019-07-04
JP2016539089A (ja) 2016-12-15
IL244976A0 (en) 2016-05-31
US9512224B2 (en) 2016-12-06
MX385575B (es) 2025-03-18
SG11201602807PA (en) 2016-05-30
AU2014331683A1 (en) 2016-04-28
PT3054976T (pt) 2020-08-05
BR112016008010A2 (pt) 2017-09-26
EP3054976B1 (en) 2020-07-08
EA201690728A1 (ru) 2016-08-31
IL244976B (en) 2020-07-30
ZA201602577B (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112016010169A2 (pt) anticorpos anticlaudina e métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112015025347A2 (pt) 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
BR112015023589A8 (pt) Método para a produção de um conjugado de imunoligante/carga útil, conjugado, uso de um conjugado, carga útil de baixo peso molecular e uso de uma carga útil
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112014020826A2 (pt) moduladores e métodos de uso
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
MX2015004771A (es) Metodos para tratar cancer.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016014731A2 (pt) Anticorpos anti-baff
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
MX2013011921A (es) Compuestos de benceno substituidos con arilo o heterorilo.
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso